ImmunOs Therapeutics
Series C in 2024
ImmunOs Therapeutics AG is a clinical-stage biotechnology company based in Schlieren, Switzerland, founded in 2014. The company specializes in the discovery and development of innovative immunotherapies aimed at enhancing cancer treatment and addressing autoimmune diseases. ImmunOs focuses on creating novel human immunomodulatory proteins that play a role in both innate and adaptive immunity. Their therapeutics are designed to exert direct anti-tumor effects by remodeling the tumor microenvironment, while also developing antibodies that inhibit the activation of specific HLA molecules linked to autoimmune conditions. Through its research and development efforts, ImmunOs aims to improve the lives of patients facing serious diseases.
TOLREMO therapeutics
Series A in 2023
TOLREMO therapeutics AG is a biotechnology company based in Muttenz, Switzerland, specializing in the development of small molecule therapies aimed at addressing drug resistance in cancer treatment. Founded in 2017, TOLREMO focuses on creating innovative drug discovery engines and therapies that target novel resistance pathways in cancer cells. The company’s approach involves developing add-on therapies that enhance the effectiveness of existing oncogene-targeting drugs by dismantling the initial defenses against these treatments. By specifically targeting and eradicating cancer cells responsible for drug resistance, TOLREMO aims to provide personalized anti-drug resistance therapies that significantly prolong the lives of cancer patients and improve treatment response rates.
TRiCares is a medical device company focused on creating innovative solutions for tricuspid valve regurgitation. The company specializes in developing a catheter-based valve replacement system that facilitates minimally invasive treatments for patients suffering from tricuspid insufficiency. By emphasizing anatomical conformation and user-friendly design, TRiCares aims to provide effective and durable treatment options that improve patient outcomes. Through its advancements in medical technology, TRiCares addresses a critical need in cardiology, enhancing the quality of care for those affected by this condition.
ImmunOs Therapeutics
Series B in 2022
ImmunOs Therapeutics AG is a clinical-stage biotechnology company based in Schlieren, Switzerland, founded in 2014. The company specializes in the discovery and development of innovative immunotherapies aimed at enhancing cancer treatment and addressing autoimmune diseases. ImmunOs focuses on creating novel human immunomodulatory proteins that play a role in both innate and adaptive immunity. Their therapeutics are designed to exert direct anti-tumor effects by remodeling the tumor microenvironment, while also developing antibodies that inhibit the activation of specific HLA molecules linked to autoimmune conditions. Through its research and development efforts, ImmunOs aims to improve the lives of patients facing serious diseases.
Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.
Precirix is a biotechnology company based in Brussels, Belgium, focused on the development of radio-immunotherapeutic drugs aimed at treating cancer patients. Established in 2014, the company utilizes the unique properties of the camelid immune system to create targeted therapies. Its innovative approach involves using antigen-binding fragments to deliver therapeutic radioisotopes directly to specific receptors on cancer cells. This method allows for a more personalized treatment option, enhancing the effectiveness of cancer therapies while minimizing damage to healthy tissue. Precirix is dedicated to advancing the field of oncology through its specialized drug development, contributing to improved outcomes for patients with various types of cancer.
Scenic Biotech
Series A in 2022
Scenic Biotech, established in 2017 and headquartered in Amsterdam, Netherlands, specializes in developing genomics and immunotherapy technologies to combat cancer and rare genetic diseases. The company's core focus is to identify and harness disease-suppressing genes, which can act as an "off-switch" for genetic disorders, thereby creating novel drug targets and therapies. By leveraging genomics, Scenic Biotech aims to revolutionize the treatment of severe diseases by tackling them at the genetic level.
Cardior Pharmaceuticals
Series B in 2021
Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, founded in 2016. The company specializes in developing non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is the leading cause of death in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a critical microRNA responsible for pathological changes in the heart resulting from stress or injury. Through its innovative approach, Cardior Pharmaceuticals seeks to address significant unmet medical needs in cardiovascular health.
Topas Therapeutics
Series B in 2021
Topas Therapeutics GmbH, established in 2013 and based in Hamburg, Germany, is a biotechnology company specializing in the development of nanoparticle-based therapeutics. The company's core focus is to induce antigen-specific immune tolerance, utilizing the liver's natural immunology capabilities to treat autoimmune diseases, allergies, and anti-drug antibodies. Topas' proprietary platform, Topas Particle Conjugates, targets liver sinusoidal endothelial cells, enabling tolerance against blood-borne antigens. The company has several clinical-stage programs, including TPM203 for pemphigus vulgaris, and collaborations with pharmaceutical giants like Eli Lilly and Boehringer Ingelheim. Topas Therapeutics is backed by prominent investors such as Epidarex Capital, Gimv, EMBL Ventures, Evotec, and Boehringer Ingelheim Venture Fund.
Alentis Therapeutics
Series B in 2021
Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, specializing in the development of innovative therapies for advanced liver diseases and cancers associated with Claudin-1 (CLDN1) expression. Founded in 2019, Alentis focuses on addressing conditions such as liver fibrosis, cirrhosis, and liver cancer through the use of anti-CLDN1 antibody-drug conjugates and other targeted treatments. The company's unique approach combines clinically relevant read-outs with advanced techniques like single-cell RNA sequencing of patient liver tissues, aiming to reverse disease progression and improve patient outcomes. Alentis Therapeutics is recognized for its pioneering role in exploring anti-CLDN1 therapeutics, contributing to advancements in the treatment of fibrotic diseases and CLDN1-positive tumors.
Noema Pharma
Series A in 2020
Noema Pharma AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing innovative therapeutic products for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts are dedicated to addressing disabling symptoms associated with conditions affecting the nervous system, such as Tuberous Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By creating novel therapies, Noema Pharma aims to enhance the quality of life and improve patient outcomes for those suffering from these challenging disorders.
Topas Therapeutics
Series B in 2020
Topas Therapeutics GmbH, established in 2013 and based in Hamburg, Germany, is a biotechnology company specializing in the development of nanoparticle-based therapeutics. The company's core focus is to induce antigen-specific immune tolerance, utilizing the liver's natural immunology capabilities to treat autoimmune diseases, allergies, and anti-drug antibodies. Topas' proprietary platform, Topas Particle Conjugates, targets liver sinusoidal endothelial cells, enabling tolerance against blood-borne antigens. The company has several clinical-stage programs, including TPM203 for pemphigus vulgaris, and collaborations with pharmaceutical giants like Eli Lilly and Boehringer Ingelheim. Topas Therapeutics is backed by prominent investors such as Epidarex Capital, Gimv, EMBL Ventures, Evotec, and Boehringer Ingelheim Venture Fund.
Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.
TOLREMO therapeutics
Series A in 2020
TOLREMO therapeutics AG is a biotechnology company based in Muttenz, Switzerland, specializing in the development of small molecule therapies aimed at addressing drug resistance in cancer treatment. Founded in 2017, TOLREMO focuses on creating innovative drug discovery engines and therapies that target novel resistance pathways in cancer cells. The company’s approach involves developing add-on therapies that enhance the effectiveness of existing oncogene-targeting drugs by dismantling the initial defenses against these treatments. By specifically targeting and eradicating cancer cells responsible for drug resistance, TOLREMO aims to provide personalized anti-drug resistance therapies that significantly prolong the lives of cancer patients and improve treatment response rates.
Azafaros B.V., based in Leiden, the Netherlands, specializes in the development of therapeutic agents aimed at treating rare metabolic disorders, specifically lysosomal storage disorders. The company focuses on innovative oral medications made from aza-sugar compounds, which were originally discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC, and have been exclusively licensed to Azafaros. These promising therapeutic agents are designed to address critical disease pathways by targeting the central nervous system and altering the metabolism of glycosphingolipids through a unique dual mode of action. Azafaros seeks to improve patient outcomes and enhance the quality of life for individuals affected by these severe inherited conditions.
Aleva Neurotherapeutics
Series E in 2019
Aleva Neurotherapeutics SA is a Swiss company specializing in the development of advanced implantable deep brain stimulation (DBS) systems. Founded in 2008 and based in Lausanne, Aleva focuses on creating next-generation neurostimulation devices that utilize microelectromechanical systems (MEMS) technology. Its flagship product, directSTIM, features an array of directional microelectrodes that enable precise electrical stimulation, enhancing the efficacy of DBS therapy for conditions such as Parkinson's disease and essential tremor. In addition, Aleva has developed spiderSTIM, a diagnostic system that maps three-dimensional brain targets to optimize stimulation, and cortiSTIM, designed for cortical stimulation. The company is committed to maximizing the potential of its technology by launching a series of therapeutic products while carefully managing development risks. Aleva Neurotherapeutics is ISO13485 certified, underscoring its dedication to quality and safety in the medical device sector.
ImmunOs Therapeutics
Series A in 2019
ImmunOs Therapeutics AG is a clinical-stage biotechnology company based in Schlieren, Switzerland, founded in 2014. The company specializes in the discovery and development of innovative immunotherapies aimed at enhancing cancer treatment and addressing autoimmune diseases. ImmunOs focuses on creating novel human immunomodulatory proteins that play a role in both innate and adaptive immunity. Their therapeutics are designed to exert direct anti-tumor effects by remodeling the tumor microenvironment, while also developing antibodies that inhibit the activation of specific HLA molecules linked to autoimmune conditions. Through its research and development efforts, ImmunOs aims to improve the lives of patients facing serious diseases.
Alentis Therapeutics
Series A in 2019
Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, specializing in the development of innovative therapies for advanced liver diseases and cancers associated with Claudin-1 (CLDN1) expression. Founded in 2019, Alentis focuses on addressing conditions such as liver fibrosis, cirrhosis, and liver cancer through the use of anti-CLDN1 antibody-drug conjugates and other targeted treatments. The company's unique approach combines clinically relevant read-outs with advanced techniques like single-cell RNA sequencing of patient liver tissues, aiming to reverse disease progression and improve patient outcomes. Alentis Therapeutics is recognized for its pioneering role in exploring anti-CLDN1 therapeutics, contributing to advancements in the treatment of fibrotic diseases and CLDN1-positive tumors.
Precirix is a biotechnology company based in Brussels, Belgium, focused on the development of radio-immunotherapeutic drugs aimed at treating cancer patients. Established in 2014, the company utilizes the unique properties of the camelid immune system to create targeted therapies. Its innovative approach involves using antigen-binding fragments to deliver therapeutic radioisotopes directly to specific receptors on cancer cells. This method allows for a more personalized treatment option, enhancing the effectiveness of cancer therapies while minimizing damage to healthy tissue. Precirix is dedicated to advancing the field of oncology through its specialized drug development, contributing to improved outcomes for patients with various types of cancer.
Amal Therapeutics
Series B in 2018
Amal Therapeutics SA, established in 2012 in Geneva, Switzerland, is a biotechnology company focused on developing therapeutic vaccines for oncology. It utilizes its proprietary cell penetrating peptide platform to create and advance cancer vaccines designed to stimulate the immune system's cellular response against tumors. As of mid-2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.
TOLREMO therapeutics
Series A in 2018
TOLREMO therapeutics AG is a biotechnology company based in Muttenz, Switzerland, specializing in the development of small molecule therapies aimed at addressing drug resistance in cancer treatment. Founded in 2017, TOLREMO focuses on creating innovative drug discovery engines and therapies that target novel resistance pathways in cancer cells. The company’s approach involves developing add-on therapies that enhance the effectiveness of existing oncogene-targeting drugs by dismantling the initial defenses against these treatments. By specifically targeting and eradicating cancer cells responsible for drug resistance, TOLREMO aims to provide personalized anti-drug resistance therapies that significantly prolong the lives of cancer patients and improve treatment response rates.
TRiCares is a medical device company focused on creating innovative solutions for tricuspid valve regurgitation. The company specializes in developing a catheter-based valve replacement system that facilitates minimally invasive treatments for patients suffering from tricuspid insufficiency. By emphasizing anatomical conformation and user-friendly design, TRiCares aims to provide effective and durable treatment options that improve patient outcomes. Through its advancements in medical technology, TRiCares addresses a critical need in cardiology, enhancing the quality of care for those affected by this condition.
Miracor Medical
Series D in 2018
Miracor Medical is a medical device company that specializes in developing clinical devices aimed at treating severe cardiac diseases. Founded in 2008 and headquartered in Awans, Belgium, the company is known for its PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion technology. This innovative system is designed to assist cardiac surgeons in treating patients experiencing myocardial infarction during coronary artery bypass grafting procedures. By enhancing microvascular perfusion through the coronary sinus, the PiCSO Impulse System aims to reduce infarct size, improve cardiac function, and potentially decrease the likelihood of heart failure following acute myocardial infarction.
Hookipa Pharma
Series C in 2017
Hookipa Pharma Inc. is a clinical stage biopharmaceutical company focused on developing innovative immunotherapeutics for infectious diseases and cancers through its proprietary arenavirus platform. The company employs its advanced Vaxwave and TheraT technologies to stimulate robust immune responses, generating antigen-specific killer T cells and antibodies. Hookipa's lead candidate for infectious diseases, HB-101, is currently undergoing a Phase II clinical trial targeting patients awaiting kidney transplants from cytomegalovirus-positive donors. In oncology, its product candidates HB-201 and HB-202 are in preclinical studies aimed at treating human papillomavirus-positive cancers. Additionally, Hookipa collaborates with Gilead Sciences to create therapies for chronic Hepatitis B and HIV infections. Founded in 2011, the company is headquartered in New York, New York.
Amal Therapeutics
Series B in 2017
Amal Therapeutics SA, established in 2012 in Geneva, Switzerland, is a biotechnology company focused on developing therapeutic vaccines for oncology. It utilizes its proprietary cell penetrating peptide platform to create and advance cancer vaccines designed to stimulate the immune system's cellular response against tumors. As of mid-2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.
Cardior Pharmaceuticals
Series A in 2017
Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, founded in 2016. The company specializes in developing non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is the leading cause of death in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a critical microRNA responsible for pathological changes in the heart resulting from stress or injury. Through its innovative approach, Cardior Pharmaceuticals seeks to address significant unmet medical needs in cardiovascular health.
Hookipa Pharma
Series B in 2016
Hookipa Pharma Inc. is a clinical stage biopharmaceutical company focused on developing innovative immunotherapeutics for infectious diseases and cancers through its proprietary arenavirus platform. The company employs its advanced Vaxwave and TheraT technologies to stimulate robust immune responses, generating antigen-specific killer T cells and antibodies. Hookipa's lead candidate for infectious diseases, HB-101, is currently undergoing a Phase II clinical trial targeting patients awaiting kidney transplants from cytomegalovirus-positive donors. In oncology, its product candidates HB-201 and HB-202 are in preclinical studies aimed at treating human papillomavirus-positive cancers. Additionally, Hookipa collaborates with Gilead Sciences to create therapies for chronic Hepatitis B and HIV infections. Founded in 2011, the company is headquartered in New York, New York.
Miracor Medical
Series C in 2016
Miracor Medical is a medical device company that specializes in developing clinical devices aimed at treating severe cardiac diseases. Founded in 2008 and headquartered in Awans, Belgium, the company is known for its PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion technology. This innovative system is designed to assist cardiac surgeons in treating patients experiencing myocardial infarction during coronary artery bypass grafting procedures. By enhancing microvascular perfusion through the coronary sinus, the PiCSO Impulse System aims to reduce infarct size, improve cardiac function, and potentially decrease the likelihood of heart failure following acute myocardial infarction.
Aleva Neurotherapeutics
Series C in 2016
Aleva Neurotherapeutics SA is a Swiss company specializing in the development of advanced implantable deep brain stimulation (DBS) systems. Founded in 2008 and based in Lausanne, Aleva focuses on creating next-generation neurostimulation devices that utilize microelectromechanical systems (MEMS) technology. Its flagship product, directSTIM, features an array of directional microelectrodes that enable precise electrical stimulation, enhancing the efficacy of DBS therapy for conditions such as Parkinson's disease and essential tremor. In addition, Aleva has developed spiderSTIM, a diagnostic system that maps three-dimensional brain targets to optimize stimulation, and cortiSTIM, designed for cortical stimulation. The company is committed to maximizing the potential of its technology by launching a series of therapeutic products while carefully managing development risks. Aleva Neurotherapeutics is ISO13485 certified, underscoring its dedication to quality and safety in the medical device sector.
Anergis is a clinical-stage biopharmaceutical company based in Lausanne, Switzerland, founded in 2001 by Francois Spertini. The company specializes in the discovery and development of allergy vaccines utilizing a proprietary technology known as Contiguous Overlapping Peptides, aimed at enabling ultra-fast desensitization for patients with allergies. Anergis offers immunotherapy solutions targeting common allergens such as birch pollen, ragweed pollen, and house dust mites. Their innovative approach focuses on providing disease-modifying treatments that seek to deliver long-term cures for allergies, ultimately reducing treatment time and improving the overall medical management of allergy sufferers.
Sequana Medical
Series C in 2015
Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.
Miracor Medical
Series B in 2015
Miracor Medical is a medical device company that specializes in developing clinical devices aimed at treating severe cardiac diseases. Founded in 2008 and headquartered in Awans, Belgium, the company is known for its PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion technology. This innovative system is designed to assist cardiac surgeons in treating patients experiencing myocardial infarction during coronary artery bypass grafting procedures. By enhancing microvascular perfusion through the coronary sinus, the PiCSO Impulse System aims to reduce infarct size, improve cardiac function, and potentially decrease the likelihood of heart failure following acute myocardial infarction.
Genkyotex
Series D in 2015
Genkyotex SA is a biopharmaceutical company focused on developing innovative oral small molecule therapies that selectively inhibit NOX enzymes involved in various disease processes, including fibrosis, inflammation, pain, cancer, and neurodegeneration. Its lead candidate, GKT831, targets NOX1 and NOX4 and is currently undergoing Phase II clinical trials for primary biliary cholangitis and type 1 diabetes-related kidney disease. Additionally, Genkyotex is advancing a preclinical candidate, GKT771, which inhibits NOX1 and aims to address pain processing and inflammation. The company also holds a license agreement with the Serum Institute of India for GTL003, an antigen intended for developing combination vaccines against infectious diseases. Established in 2006 and headquartered in Labège, France, Genkyotex is committed to improving treatment options for chronic diseases through its novel therapeutic approaches.
Anergis is a clinical-stage biopharmaceutical company based in Lausanne, Switzerland, founded in 2001 by Francois Spertini. The company specializes in the discovery and development of allergy vaccines utilizing a proprietary technology known as Contiguous Overlapping Peptides, aimed at enabling ultra-fast desensitization for patients with allergies. Anergis offers immunotherapy solutions targeting common allergens such as birch pollen, ragweed pollen, and house dust mites. Their innovative approach focuses on providing disease-modifying treatments that seek to deliver long-term cures for allergies, ultimately reducing treatment time and improving the overall medical management of allergy sufferers.
AYOXXA Biosystems GmbH is a life science tools company based in Cologne, Germany, with additional offices in Singapore and Boston, Massachusetts. Founded in 2010, AYOXXA specializes in developing a proprietary technology platform for multiplexed protein analysis. This platform, which utilizes In-situ Encoded Bead-based Arrays, enables users to simultaneously measure multiple protein markers associated with various health conditions, including cancer, allergies, cardiovascular diseases, and infectious diseases. AYOXXA's innovative biochips merge biological analysis with information technology, expanding the potential applications in biomedical research. The company also offers biomarker kits to facilitate the identification and quantification of proteins and other biomolecular analytes.
Curetis AG is a Germany-based company that specializes in developing molecular diagnostics solutions for infectious diseases. Founded in 2015 and now operating as a subsidiary of OpGen, Inc., Curetis focuses on the detection of pathogens and antibiotic resistance markers. The company offers a rapid diagnostic platform that enables multiparameter testing of various analytes in a single run, providing comprehensive panels for detecting a wide range of pathogens and resistance genes. This innovative approach aims to improve patient outcomes by delivering early, actionable information to healthcare providers, particularly in the context of severe bacterial infections. Curetis's technology not only addresses current healthcare challenges but also presents opportunities for future expansions into other clinical applications beyond infectious diseases.
Humedics GmbH, founded in 2009 and based in Berlin, Germany, specializes in developing innovative solutions for liver function assessment. The company's flagship product, the LiMAx test, is a breath analysis device that enables real-time measurement of liver function in patients with liver failure. This easy-to-use bedside system includes a medical device, breath masks, and a diagnostic drug, allowing clinicians to accurately quantify liver function capacity. The LiMAx test is utilized in various clinical applications, such as evaluating liver function prior to and following liver transplantation, planning for living donor liver resection, and assessing conditions like liver cirrhosis. With its technology already benefiting thousands of patients, Humedics is actively expanding its global operations to enhance patient outcomes through tailored medical treatment.
ImevaX GmbH is a biopharmaceutical company based in Munich, Germany, founded in 2014. The company specializes in developing vaccines targeting pathogens that cause chronic infectious diseases and nosocomial infections. ImevaX's approach involves creating specific vaccines against immune evasion factors used by these pathogens to control infections. Their lead candidate is IMX 101, a vaccine designed to combat Helicobacter pylori, a bacterium that colonizes the stomach and is linked to ulcer disease and gastric cancer in humans. The company’s research focuses on understanding and neutralizing bacterial factors that down-regulate the host immune system, a mechanism used by many highly infectious pathogens. Additionally, ImevaX offers diagnostic tests for early detection of Helicobacter pylori infections.
Affimed NV is a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapies. With nearly two decades of expertise in innate immunity, Affimed seeks to leverage the innate immune system to enhance cancer treatment outcomes. The company specializes in discovering and advancing targeted therapies through its unique approach of using innate cell engagers, which aim to address the limitations of existing immuno-oncology therapies. In addition to its core research and development efforts, Affimed also generates revenue by providing research and development services to third parties, utilizing both its own and externally licensed intellectual property.
Sequana Medical
Series C in 2014
Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.
Inotrem S.A. is a biotechnology company focused on developing innovative immunotherapies for acute and chronic inflammatory conditions. The company specializes in targeting the TREM-1 pathway to modulate unbalanced inflammatory responses. Inotrem's proprietary technology platform has led to the creation of nangibotide (LR12), a first-in-class TREM-1 inhibitor with potential applications in critical medical situations such as septic shock and myocardial infarction. Additionally, Inotrem is advancing research on new therapeutic modalities aimed at addressing chronic inflammatory diseases. By leveraging its expertise in immunomodulation, Inotrem aims to provide effective treatments for patients suffering from various inflammatory syndromes, enhancing critical care solutions in healthcare.
Anergis is a clinical-stage biopharmaceutical company based in Lausanne, Switzerland, founded in 2001 by Francois Spertini. The company specializes in the discovery and development of allergy vaccines utilizing a proprietary technology known as Contiguous Overlapping Peptides, aimed at enabling ultra-fast desensitization for patients with allergies. Anergis offers immunotherapy solutions targeting common allergens such as birch pollen, ragweed pollen, and house dust mites. Their innovative approach focuses on providing disease-modifying treatments that seek to deliver long-term cures for allergies, ultimately reducing treatment time and improving the overall medical management of allergy sufferers.
Delenex Therapeutics
Series A in 2013
Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.
Hookipa Pharma
Series B in 2013
Hookipa Pharma Inc. is a clinical stage biopharmaceutical company focused on developing innovative immunotherapeutics for infectious diseases and cancers through its proprietary arenavirus platform. The company employs its advanced Vaxwave and TheraT technologies to stimulate robust immune responses, generating antigen-specific killer T cells and antibodies. Hookipa's lead candidate for infectious diseases, HB-101, is currently undergoing a Phase II clinical trial targeting patients awaiting kidney transplants from cytomegalovirus-positive donors. In oncology, its product candidates HB-201 and HB-202 are in preclinical studies aimed at treating human papillomavirus-positive cancers. Additionally, Hookipa collaborates with Gilead Sciences to create therapies for chronic Hepatitis B and HIV infections. Founded in 2011, the company is headquartered in New York, New York.
Middle Peak Medical
Series A in 2013
Middle Peak Medical is a privately held medical device company dedicated to addressing mitral valve disease through innovative technology. The company develops a proprietary device designed for both percutaneous catheter-based interventions and minimally invasive or open-heart surgical procedures. This novel device specifically targets the treatment of mitral valve regurgitation, aiming to restore proper mitral valve function in cases of both functional and degenerative conditions. By providing a new posterior surface for the anterior leaflet to seal effectively, Middle Peak Medical seeks to meet critical unmet needs in the management of mitral valve diseases.
SuppreMol
Series D in 2013
SuppreMol is a privately held biotechnology company that specializes in developing therapeutics for autoimmune and allergic diseases. The company is at the forefront of a novel approach aimed at treating these conditions by targeting their underlying causes rather than just alleviating symptoms. SuppreMol focuses on the development of soluble Fc-gamma receptors, which are recombinant autologous therapeutic proteins designed to exert specific immunoregulatory effects. This innovative strategy positions the company as a significant player in the field of immunotherapy, with the potential to advance treatment options for patients suffering from a range of autoimmune disorders.
Affimed NV is a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapies. With nearly two decades of expertise in innate immunity, Affimed seeks to leverage the innate immune system to enhance cancer treatment outcomes. The company specializes in discovering and advancing targeted therapies through its unique approach of using innate cell engagers, which aim to address the limitations of existing immuno-oncology therapies. In addition to its core research and development efforts, Affimed also generates revenue by providing research and development services to third parties, utilizing both its own and externally licensed intellectual property.
Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.
Aleva Neurotherapeutics
Series B in 2012
Aleva Neurotherapeutics SA is a Swiss company specializing in the development of advanced implantable deep brain stimulation (DBS) systems. Founded in 2008 and based in Lausanne, Aleva focuses on creating next-generation neurostimulation devices that utilize microelectromechanical systems (MEMS) technology. Its flagship product, directSTIM, features an array of directional microelectrodes that enable precise electrical stimulation, enhancing the efficacy of DBS therapy for conditions such as Parkinson's disease and essential tremor. In addition, Aleva has developed spiderSTIM, a diagnostic system that maps three-dimensional brain targets to optimize stimulation, and cortiSTIM, designed for cortical stimulation. The company is committed to maximizing the potential of its technology by launching a series of therapeutic products while carefully managing development risks. Aleva Neurotherapeutics is ISO13485 certified, underscoring its dedication to quality and safety in the medical device sector.
Aleva Neurotherapeutics
Series A in 2011
Aleva Neurotherapeutics SA is a Swiss company specializing in the development of advanced implantable deep brain stimulation (DBS) systems. Founded in 2008 and based in Lausanne, Aleva focuses on creating next-generation neurostimulation devices that utilize microelectromechanical systems (MEMS) technology. Its flagship product, directSTIM, features an array of directional microelectrodes that enable precise electrical stimulation, enhancing the efficacy of DBS therapy for conditions such as Parkinson's disease and essential tremor. In addition, Aleva has developed spiderSTIM, a diagnostic system that maps three-dimensional brain targets to optimize stimulation, and cortiSTIM, designed for cortical stimulation. The company is committed to maximizing the potential of its technology by launching a series of therapeutic products while carefully managing development risks. Aleva Neurotherapeutics is ISO13485 certified, underscoring its dedication to quality and safety in the medical device sector.
Curetis AG is a Germany-based company that specializes in developing molecular diagnostics solutions for infectious diseases. Founded in 2015 and now operating as a subsidiary of OpGen, Inc., Curetis focuses on the detection of pathogens and antibiotic resistance markers. The company offers a rapid diagnostic platform that enables multiparameter testing of various analytes in a single run, providing comprehensive panels for detecting a wide range of pathogens and resistance genes. This innovative approach aims to improve patient outcomes by delivering early, actionable information to healthcare providers, particularly in the context of severe bacterial infections. Curetis's technology not only addresses current healthcare challenges but also presents opportunities for future expansions into other clinical applications beyond infectious diseases.
Delenex Therapeutics
Series A in 2011
Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.
Anergis is a clinical-stage biopharmaceutical company based in Lausanne, Switzerland, founded in 2001 by Francois Spertini. The company specializes in the discovery and development of allergy vaccines utilizing a proprietary technology known as Contiguous Overlapping Peptides, aimed at enabling ultra-fast desensitization for patients with allergies. Anergis offers immunotherapy solutions targeting common allergens such as birch pollen, ragweed pollen, and house dust mites. Their innovative approach focuses on providing disease-modifying treatments that seek to deliver long-term cures for allergies, ultimately reducing treatment time and improving the overall medical management of allergy sufferers.
Sequana Medical
Series B in 2011
Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.
Activaero
Series A in 2011
Activaero GmbH is a drug delivery company specializing in controlled breathing technologies designed for the pulmonary delivery of inhaled therapeutic agents. Founded in 2004 and based in Gemunden, Germany, with additional locations in Munich and Dublin, Ohio, Activaero develops innovative devices such as AKITA, which utilizes smart card technology for efficient drug delivery, and Watchhaler, specifically designed for children requiring inhaled medication. The company also offers AKITA², a technology for use in clinical trials, and LimiX, a flow limitation valve that regulates inhalation flow rates. In addition to its product offerings, Activaero provides measurement and diagnostic technologies for laboratory applications, including aerosol property measurement systems. Furthermore, the company engages in contract development and clinical trial logistics services, marketing its products through a network of distributors. Activaero's solutions aim to improve therapy outcomes for patients suffering from severe respiratory diseases, including asthma, chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis.
Vaximm
Venture Round in 2011
Vaximm is a biotechnology company dedicated to developing active immunotherapies, specifically vaccines, for cancer patients. Their primary focus is on targeting the tumor vasculature, which is crucial for tumor growth. The company's initial product candidate, VXM01, has demonstrated significant anti-tumor activity in various animal studies and was set to enter first human clinical trials in 2011. Vaximm's vaccines utilize oral T-cell activators based on modified attenuated bacteria, designed to target a broad range of cancer-related antigens, offering advanced treatment options for cancer patients.
SuppreMol
Series C in 2010
SuppreMol is a privately held biotechnology company that specializes in developing therapeutics for autoimmune and allergic diseases. The company is at the forefront of a novel approach aimed at treating these conditions by targeting their underlying causes rather than just alleviating symptoms. SuppreMol focuses on the development of soluble Fc-gamma receptors, which are recombinant autologous therapeutic proteins designed to exert specific immunoregulatory effects. This innovative strategy positions the company as a significant player in the field of immunotherapy, with the potential to advance treatment options for patients suffering from a range of autoimmune disorders.
Delenex Therapeutics
Series A in 2010
Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.
Affimed NV is a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapies. With nearly two decades of expertise in innate immunity, Affimed seeks to leverage the innate immune system to enhance cancer treatment outcomes. The company specializes in discovering and advancing targeted therapies through its unique approach of using innate cell engagers, which aim to address the limitations of existing immuno-oncology therapies. In addition to its core research and development efforts, Affimed also generates revenue by providing research and development services to third parties, utilizing both its own and externally licensed intellectual property.
Evolva is a biotechnology company based in Reinach, Switzerland, that specializes in the development and commercialization of nature-based ingredients and innovative small-molecule compounds. Founded in 2004, Evolva leverages a proprietary synthetic biology platform to create high-quality ingredients that serve various applications, including flavors, fragrances, health ingredients, and health protection. By mimicking the chemical structures found in natural products, Evolva's technology offers solutions that avoid the limitations associated with traditional methods, thus providing a versatile approach to ingredient formulation and product development.
Curetis AG is a Germany-based company that specializes in developing molecular diagnostics solutions for infectious diseases. Founded in 2015 and now operating as a subsidiary of OpGen, Inc., Curetis focuses on the detection of pathogens and antibiotic resistance markers. The company offers a rapid diagnostic platform that enables multiparameter testing of various analytes in a single run, providing comprehensive panels for detecting a wide range of pathogens and resistance genes. This innovative approach aims to improve patient outcomes by delivering early, actionable information to healthcare providers, particularly in the context of severe bacterial infections. Curetis's technology not only addresses current healthcare challenges but also presents opportunities for future expansions into other clinical applications beyond infectious diseases.
Activaero
Series A in 2009
Activaero GmbH is a drug delivery company specializing in controlled breathing technologies designed for the pulmonary delivery of inhaled therapeutic agents. Founded in 2004 and based in Gemunden, Germany, with additional locations in Munich and Dublin, Ohio, Activaero develops innovative devices such as AKITA, which utilizes smart card technology for efficient drug delivery, and Watchhaler, specifically designed for children requiring inhaled medication. The company also offers AKITA², a technology for use in clinical trials, and LimiX, a flow limitation valve that regulates inhalation flow rates. In addition to its product offerings, Activaero provides measurement and diagnostic technologies for laboratory applications, including aerosol property measurement systems. Furthermore, the company engages in contract development and clinical trial logistics services, marketing its products through a network of distributors. Activaero's solutions aim to improve therapy outcomes for patients suffering from severe respiratory diseases, including asthma, chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis.
Evolva is a biotechnology company based in Reinach, Switzerland, that specializes in the development and commercialization of nature-based ingredients and innovative small-molecule compounds. Founded in 2004, Evolva leverages a proprietary synthetic biology platform to create high-quality ingredients that serve various applications, including flavors, fragrances, health ingredients, and health protection. By mimicking the chemical structures found in natural products, Evolva's technology offers solutions that avoid the limitations associated with traditional methods, thus providing a versatile approach to ingredient formulation and product development.
Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.
Lumavita AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development and commercialization of novel anti-infectives aimed at women's health. Founded in 2008, Lumavita focuses on addressing infections that affect women, with key products including FemiFect, an antibiotic designed to treat vaginitis caused by various pathogens, and SPK-601, which targets human papilloma virus (HPV) and herpes simplex virus (HSV). The company operates as a subsidiary of Shogoo Pharmaceuticals KK and distributes its products through a network of distributors. Lumavita AG was previously known as Shogoo Pharmaceuticals, AG before rebranding in 2007.
ESBATech, founded in 1998 as a spin-out from the University of Zurich, specializes in developing fully human antibody fragments for therapeutic use. The company utilizes its proprietary single-chain antibody frameworks to create product candidates targeting clinically relevant sites. ESBATech's approach aims to deliver high concentrations of these therapeutic fragments directly to targeted areas while minimizing systemic exposure, thereby reducing the risk of adverse drug reactions through topical and local administration methods.
SuppreMol
Series B in 2008
SuppreMol is a privately held biotechnology company that specializes in developing therapeutics for autoimmune and allergic diseases. The company is at the forefront of a novel approach aimed at treating these conditions by targeting their underlying causes rather than just alleviating symptoms. SuppreMol focuses on the development of soluble Fc-gamma receptors, which are recombinant autologous therapeutic proteins designed to exert specific immunoregulatory effects. This innovative strategy positions the company as a significant player in the field of immunotherapy, with the potential to advance treatment options for patients suffering from a range of autoimmune disorders.
Vivendy Therapeutics
Series A in 2007
Vivendy Therapeutics Ltd. is a biopharmaceutical company based in Basel, Switzerland, focused on developing innovative treatments for rare lysosomal storage diseases. Founded in 2006, the company is primarily engaged in creating an enzyme replacement therapy for Morbus Morquio, also known as MPS IVA, which is caused by a deficiency in a specific enzyme. Vivendy has developed a recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that has been specifically modified to enhance enzyme activity, significantly improving the efficacy of the therapy. Through its research and development efforts, Vivendy Therapeutics aims to address the unmet medical needs of patients suffering from this rare condition.
Idiag
Venture Round in 2007
Idiag AG is a Swiss company that specializes in designing, manufacturing, and marketing healthcare equipment aimed at improving health and performance. Founded in 1993 and based in Fehraltorf, the company offers a range of products, including SpinalMouse for back assessments, STMedical for respiratory therapy, SpiroTiger for respiratory training, and the Biacorpus RX 4000 for body composition analysis. Additionally, Idiag provides solutions for weight management, spinal analysis, and therapy, catering to a diverse clientele that includes doctors, physiotherapists, medical personnel, and both professional and recreational athletes. The company focuses on converting innovative medical technology ideas into market-ready products, collaborating with universities and innovation centers for development and marketing. Idiag markets its products through dealers in Switzerland, Germany, and other international markets, leveraging its resources and networks for effective sales and market penetration.
Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.
Affimed NV is a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapies. With nearly two decades of expertise in innate immunity, Affimed seeks to leverage the innate immune system to enhance cancer treatment outcomes. The company specializes in discovering and advancing targeted therapies through its unique approach of using innate cell engagers, which aim to address the limitations of existing immuno-oncology therapies. In addition to its core research and development efforts, Affimed also generates revenue by providing research and development services to third parties, utilizing both its own and externally licensed intellectual property.
Okairos AG is a biopharmaceutical company headquartered in Basel, Switzerland, with operations in Rome and Naples, Italy. The company specializes in the discovery and development of genetic T-cell vaccines, focusing on conditions such as hepatitis C virus. Okairos also excels in gene delivery technologies, providing expertise in scalable viral-vector manufacturing processes. This enables other biotech firms to transition genetic vaccines and medicinal products from preclinical stages to commercial readiness, utilizing advanced good manufacturing practice (GMP) facilities. Previously a subsidiary of Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa, Okairos is dedicated to advancing innovative therapeutic solutions in the healthcare sector.
Santhera Pharmaceuticals
Series C in 2006
Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company dedicated to the development and commercialization of innovative products aimed at treating mitochondrial and neuromuscular diseases. This field encompasses numerous orphan and niche indications with significant unmet medical needs and limited existing therapies. The company's operations primarily focus on neuro-ophthalmological, pulmonary, and neuromuscular conditions. Santhera generates a substantial portion of its revenue from the European Union, leveraging its expertise to address critical health challenges in these specialized areas.
ESBATech, founded in 1998 as a spin-out from the University of Zurich, specializes in developing fully human antibody fragments for therapeutic use. The company utilizes its proprietary single-chain antibody frameworks to create product candidates targeting clinically relevant sites. ESBATech's approach aims to deliver high concentrations of these therapeutic fragments directly to targeted areas while minimizing systemic exposure, thereby reducing the risk of adverse drug reactions through topical and local administration methods.
EyeSense AG
Series A in 2006
EyeSense AG specializes in the development of ophthalmic diagnostic systems aimed at improving glucose testing for diabetic patients. The company focuses on creating innovative, pain-free blood glucose monitoring devices that facilitate better diabetes management. By utilizing advanced fiber optic sensors, EyeSense AG's technology enables continuous blood sugar measurement, thereby enhancing the therapy and care available to individuals with diabetes.
Bioheart
Venture Round in 2005
Bioheart, Inc. is dedicated to advancing the field of regenerative medicine by offering the highest quality technology, cellular treatments and training. Specific to biotechnology, Bioheart, Inc. specializes in the discovery, development and commercialization of autologous cellular therapies that treat a wide variety of degenerative diseases. Bioheart, Inc. is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry by delivering stem cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions, chronic and acute heart damage, peripheral vascular disease and other issues. Bioheart's goals are to improve a patient’s quality of life by regenerating their damaged tissue, when possible, and by reducing health care costs and hospitalizations. Bioheart’s leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.
Spinal Cord Therapeutics GmbH
Series A in 2005
Spinal Cord Therapeutics GmbH develops treatments for spinal cord injury. Spinal Cord Therapeutics focuses on the treatment of traumatic injury to the central nervous system.
Dolthera GmbH
Series B in 2005
Dolthera GmbH is a biopharmaceutical company that is developing an innovative class of nucleic-acid-based anti-inflammatory drugs. These drugs, based on oligonucleotides that act as decoys for disease-related transcription factors are all directed against biologically validated targets in major chronic diseases with high unmet medical need. With this business concept and the underlying patent-protected technologies, AVONTEC won in 2003 the prestigious German Founders Award that is backed by McKinsey & Company. Initially, the Company has chosen to focus its patented technology on chronic inflammatory respiratory system and skin diseases. AVONTEC currently has five programs in respiratory disease, skin disease, transplant rejection, cardiovascular disease and autoimmune disease under development. All these indications represent areas with high unmet medical need and strong commercial potential.
Symetis is a Swiss company based in Ecublens that specializes in developing innovative minimally invasive heart valve replacement therapies. The company focuses on improving patient care and safety through its proprietary Acurate™ Aortic Valve Replacement System, which features a unique self-positioning design. This design allows for easier implant positioning and alignment, enhancing the overall user experience for healthcare providers. Symetis aims to address the needs of patients suffering from aortic valve stenosis, enabling the effective treatment of severe cardiac valve conditions through its advanced transcatheter aortic valve implantation devices.
4-Antibody
Seed Round in 2004
4-Antibody AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development of human antibody therapeutics with a focus on immuno-oncology. Founded in 2002, the company utilizes its proprietary Retrocyte Display technology, which generates therapeutic antibody drug candidates from human antibody libraries expressed in mammalian B-lineage lymphocytes. In addition to providing its drug discovery platform to pharmaceutical partners, 4-Antibody is actively developing a pipeline of preclinical antibody programs targeting various immune checkpoints, including GITR, OX40, CTLA-4, PD-1, TIM-3, and LAG-3.
CareX SA is a biopharmaceutical company that develops novel treatments for metabolic and immune system disorders which includes diabetes and obesity. The company focuses on metabolic syndrome, a cluster of inter-related disorders of the body’s metabolism, including high blood pressure, high insulin levels, excess body weight, and abnormal cholesterol levels, that exposes individuals to the development of type 2 diabetes, heart diseases, and strokes. CareX SA is a France-based company that was founded in 2001 and the company was acquired by 7TM Pharma on May 24, 2006.
Thommen Medical
Series C in 2003
Thommen Medical is a medical device company that specializes in the development, production, and sale of dental implants, marketed under the brand name SPI (Swiss Precision Implant). The company focuses on creating innovative and well-designed implant systems that enhance patient comfort during procedures and ensure long-term stability of the implants. Thommen Medical collaborates with leading scientific and dental clinicians to ensure that its products meet high standards of precision and usability. In addition to dental implants, the company also offers biomaterial solutions aimed at bone and tissue regeneration, further contributing to advancements in dental health and restoration.
Roche Glycart
Series A in 2003
Roche Glycart develops antibody drug candidates, which include GA101, a humanized anti-CD20 monoclonal antibody to increase direct- and immune-mediated target cell death; and GA201, a humanized glycoengineered antibody for solid tumors.
ESBATech, founded in 1998 as a spin-out from the University of Zurich, specializes in developing fully human antibody fragments for therapeutic use. The company utilizes its proprietary single-chain antibody frameworks to create product candidates targeting clinically relevant sites. ESBATech's approach aims to deliver high concentrations of these therapeutic fragments directly to targeted areas while minimizing systemic exposure, thereby reducing the risk of adverse drug reactions through topical and local administration methods.